Browsing Category
Pharma Industry News
4722 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Karyopharm Therapeutics (KPTI) tees up ASCO 2026 readout as SENTRY trial shifts myelofibrosis debate
Karyopharm is taking its Phase 3 SENTRY myelofibrosis data to ASCO 2026. Read why the late-breaking slot matters for KPTI and selinexor now.
Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing
Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.
Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership
Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis.
Invion (ASX: IVX) just unlocked the door to 80% of skin cancers — here is what the data shows so far
Invion Limited (ASX: IVX) advances INV043 into basal cell carcinoma after second positive SCC data set. Read what this means for the trial and the company. →
Why a tiny cancer biotech suddenly looks worth more than $2bn to Eli Lilly
Eli Lilly is reportedly nearing a $2 billion-plus Kelonia deal. Read what it could mean for Lilly’s cancer pipeline, CAR-T economics, and LLY stock.
Why Lunit’s AACR 2026 showcase could reshape how investors value AI-driven precision oncology platforms like KRX: 328130
Lunit’s AACR 2026 studies reveal how its cancer AI platform is moving beyond pathology into biomarker strategy. Read what this means for KRX: 328130.
Why overcoming VEGF TKI resistance could reshape the treatment algorithm in clear cell renal cell carcinoma
Can overcoming VEGF resistance reshape kidney cancer treatment? Explore what Kura Oncology’s latest data means for markets and strategy.
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data
Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.
Why BIOX-101 might succeed where decades of stroke research have struggled
Can BIOX-101 reshape stroke treatment timelines? Discover how Bioxodes SA’s strategy could accelerate approvals and change neurovascular care.
Why clinicians are watching SkinJect as a potential alternative to repeated Mohs surgery
Find out how SkinJect could challenge repeated Mohs surgery and reshape basal cell carcinoma care. Read the full analysis now.